SSRIs in the course of COVID‐19 pneumonia: Evidence of effectiveness of antidepressants on acute inflammation. A retrospective study DOI
Leonardo Fei, Bernardo Bozza,

Giulia Melani

et al.

Human Psychopharmacology Clinical and Experimental, Journal Year: 2023, Volume and Issue: unknown

Published: Dec. 7, 2023

Abstract Introduction Relationships between inflammation and mood have been observed in terms of pro‐inflammatory effects induced by depressive conditions and, parallel, an antidepressant‐induced favorable effect on the recovery inflammatory states. Selective serotonin reuptake inhibitor (SSRI) drugs were hypothesized to improve prognosis COVID‐19 pneumonia, a typical acute inflammation, decreased mortality rate cytokine serum levels. Methods The medical records pneumonia inpatients at Careggi University Hospital (Florence) analyzed for Interleukin 6 (IL‐6) after admission over period 22 months. Medical patients treated not discontinued until discharge with SSRI or vortioxetine identified. Two groups, one antidepressants, other treated, evaluated according mentioned parameters. Multiple linear regression logistic performed. Results entire sample composed 1236 (recovered 77.1%, deceased 22.9%). group ( n = 107) had better than untreated spite age comorbidity both being greater group. Correspondingly, IL‐6 levels significantly lower p < 0.01) group, every comparison. Conclusions Outcomes this study support hypothesis influence some antidepressants COVID‐19, possibly mediated modulation. Reduction action was confirmed.

Language: Английский

Assessing the effect of selective serotonin reuptake inhibitors in the prevention of post-acute sequelae of COVID-19 DOI Creative Commons
Hythem Sidky, Kristen Hansen, Andrew T. Girvin

et al.

Computational and Structural Biotechnology Journal, Journal Year: 2024, Volume and Issue: 24, P. 115 - 125

Published: Jan. 9, 2024

BackgroundPost-acute sequelae of COVID-19 (PASC) produce significant morbidity, prompting evaluation interventions that might lower risk. Selective serotonin reuptake inhibitors (SSRIs) potentially could modulate risk PASC via their central, hypothesized immunomodulatory, and/or antiplatelet properties although clinical trial data are lacking.Materials and MethodsThis retrospective study was conducted leveraging real-world within the National COVID Cohort Collaborative (N3C) to evaluate whether SSRIs with agonist activity at sigma-1 receptor (S1R) PASC, since agonism this may serve as a mechanism by which attenuate an inflammatory response. Additionally, determine potential benefit be traced S1R agonism. Presumed defined based on computable phenotype trained U09.9 ICD-10 diagnosis code.ResultsOf 17,908 patients identified, 1521 were exposed baseline SSRI, 1803 non-S1R 14,584 neither. Using inverse probability weighting Poisson regression, relative (RR) assessed.A 29% reduction in RR (0.704 [95% CI, 0.58-0.85]; P = 4 ×10-4) seen among who received SSRI compared unexposed 21% those receiving without (0.79 0.67 - 0.93]; 0.005).Thus, reported associated decrease PASC.

Language: Английский

Citations

15
Post-infectious irritable bowel syndrome: Focus on serotonin metabolism disturbances and gut microbiota modulation DOI
О. В. Гаус,

Aliza Fedorenko,

А. Н. Судакова

et al.

Medical alphabet, Journal Year: 2025, Volume and Issue: 34, P. 36 - 41

Published: Jan. 24, 2025

Post-infectious irritable bowel syndrome (PI–IBS) is the first phenotype of disease described in literature and most studied to date. The prevalence PI–IBS population continues grow steadily especially post-COVID-19 pandemic period. Taking into account accumulated scientific clinical data dysfunction functional axis «microbiota-gut-brain» associated with formation visceral hypersensitivity intestinal motor disorders due abnormal serotonin metabolism, increased permeability low-grade inflammation considered as a key pathogenetic factor underlying development persistence symptoms. This review article analyzes summarizes information on mechanisms changes neurohumoral regulation, well qualitative quantitative composition microbiota. In addition, possibility using probiotic therapy complex patients are presented.

Language: Английский

Citations

0
COVID-19 in the years 2020 to 2022 in Germany: effects of comorbidities and co-medications based on a large-scale database analysis DOI Creative Commons
Roland Linder,

Jonas Peltner,

A. Astvatsatourov

et al.

BMC Public Health, Journal Year: 2025, Volume and Issue: 25(1)

Published: Feb. 8, 2025

The SARS-CoV-2 pandemic was a challenge for health care systems worldwide. People with pre-existing chronic diseases have been identified as vulnerable patient groups. Furthermore, some of the drugs used these such antihypertensive discussed possible influencing factors on progression COVID-19. This study examines effect medication- and morbidity-associated risk suspected to moderate disease course is based claims data Techniker Krankenkasse, Germany's largest statutory insurance. cover years 2020 2022 include insured persons COVID-19 diagnosis from both outpatient inpatient sectors control without diagnosis. We conducted matched case-control each an (a) 10 patients (b) one form two cohorts. performed descriptive analysis describe proportion in cohorts who were diagnosed comorbidities or medication use known influence progression. Multiple logistic regression models identify In first period cohort comprised total 150,018 (13,638 cases hospitalised 136,380 infection). Study 2 included 27,238 (13,619 13,619 diagnosis). Immunodeficiencies immunosuppressives strongest modifying hospitalization populations. Other associated diabetes, hypertension, depression. shown that hospitalisation past medical history use. we demonstrated ability timely available source severity large numbers patients. Given our results, potential be useful part surveillance protocol allowing early-stage access epidemiological future pandemics.

Language: Английский

Citations

0
Could antidepressants increase mood and immunity at the same time? DOI Creative Commons

Francis Lavergne,

Thérèse M. Jay

Frontiers in Psychiatry, Journal Year: 2025, Volume and Issue: 16

Published: March 12, 2025

A review of scientific literature suggests that the use antidepressants can be broadly extended to address various forms stress and inflammation as an adjunctive therapy enhances host resistance. While effects on mood are well-documented in terms their emotional, cognitive, behavioral impacts, these aspects do not fully explain cellular mechanisms action. At level, exert trophic promote neurogenesis synaptic connectivity. Studies demonstrate improve cell survival, enhance stem proliferation, reduce danger perception (mood effects) depressed patients animal models depression. These properties highlight a deeper biological mechanism beyond mood-related benefits. The acid sphingomyelinase (ASM) theory offers more compelling explanation compared monoamine hypothesis. Antidepressants functionally inhibit ASM enzyme, thereby reducing production ceramide, which directs cells toward increased cytoprotection, reproduction, well improved mood. This also highlights research demonstrating resistance infections, immunological challenges, stress, findings support potential bolster resilience scenarios involving vaccinations, aggression, depression, even aging.

Language: Английский

Citations

0
Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use DOI

Ivan Papic,

Petra Bistrović, Ivan Krečak

et al.

Journal of Psychopharmacology, Journal Year: 2024, Volume and Issue: 38(4), P. 395 - 403

Published: March 13, 2024

Background: Due to non-consistent reports in the literature, there are uncertainties about potential benefits and harms of selective serotonin reuptake inhibitors (SSRIs) patients with Coronavirus disease 2019 (COVID-19). Aim: To investigate associations SSRIs clinical characteristics unwanted outcomes among real-life severe critical COVID-19 their relationship remdesivir (RDV) use. Methods: This retrospective cohort study evaluated a total 1558 white race treated tertiary center institution, them 779 RDV 1:1 case-matched patients. Results: A 78 (5%) were exposed during hospitalization, similarly distributed matched (5.1 4.9%). No significant SSRI use age, sex, comorbidity burden, severity present either two cohorts ( p > 0.05 for all analyses). In multivariate analyses adjusted clinically meaningful variables, was significantly associated higher mortality (adjusted odds ratio (aOR) 2.0, = 0.049) (aOR 2.22, 0.044) risk mechanical-ventilation 2.57, 0.006), venous-thromboembolism 3.69, 0.007), bacteremia Conclusions: Adverse might be potentiated by use, interactions between these drug classes exist. Although our findings raise important considerations practice, they limited nature study, lack ethnic diversity, unmeasured confounding factors. Future studies exploring underlying biological mechanisms needed.

Language: Английский

Citations

2
Impact of prior antihypertensive treatment on COVID-19 outcomes, by active ingredient DOI Creative Commons
Rosa María García-Álvarez, Maruxa Zapata‐Cachafeiro, Irene Visos‐Varela

et al.

Inflammopharmacology, Journal Year: 2024, Volume and Issue: 32(3), P. 1805 - 1815

Published: April 15, 2024

To assess the impact of prior chronic treatment with angiotensin-converting enzyme inhibitors (ACEIs)/ angiotensin-receptor blockers (ARBs), both as a group and by active ingredient, on severity (risk hospitalization mortality), progression susceptibility to COVID-19.

Language: Английский

Citations

1
The role of traditional NSAIDs and selective COX-2 inhibitors on COVID-19 outcomes: a real-world data study DOI Creative Commons
Narmeen Mallah, Irene Visos‐Varela, Bahi Takkouche

et al.

Inflammopharmacology, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 23, 2024

Language: Английский

Citations

1
Die Bedeutung von Antidepressiva bei COVID-19 und Long-COVID – Ein Scoping-Review Update DOI
Udo Bonnet, Georg Juckel

Fortschritte der Neurologie · Psychiatrie, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 23, 2024

Introduction Preclinically, fluvoxamine and other antidepressants (AD) exerted antiviral anti-inflammatory properties also against SARS-COV-2. Therfore, It makes sense to test the clinical effect of AD COVID-19 Long COVID.

Language: Английский

Citations

1
Gastrointestinal pathophysiology in long COVID: Exploring roles of microbiota dysbiosis and serotonin dysregulation in post-infectious bowel symptoms DOI Creative Commons
Linda Chia‐Hui Yu

Life Sciences, Journal Year: 2024, Volume and Issue: 358, P. 123153 - 123153

Published: Oct. 23, 2024

Language: Английский

Citations

1
Anxiety in post-covid-19 syndrome – prevalence, mechanisms and treatment DOI Creative Commons
Julius Burkauskas, Igor Branchi, Stefano Pallanti

et al.

Neuroscience Applied, Journal Year: 2023, Volume and Issue: 3, P. 103932 - 103932

Published: Dec. 24, 2023

In addition to the general impact of COVID-19 pandemic on anxiety-related mental state, anxiety and disorders have also been implicated within 'post-COVID-19 syndrome', i.e. following a SARS-CoV-2 infection. The present narrative review provides an update current state knowledge in context post-COVID-19 syndrome, epidemiological, psychological, biological factors that may contribute infection, as well therapy options available for syndrome. A multi-step systematic literature search PubMed Web Science databases was performed applying broad terms: ("anxiety" OR "anxiety disorder") AND ("COVID" "COVID-19" "corona" "pandemic" "Post-COVID" "Long-COVID"). Eligible articles published until November 15, 2022 were included. Meta-analyses identified prevalence rates ranging from 16.6% 29.6% after Premorbid has not reliably shown be associated with Female sex, older age, severity hospitalization, reduced mobility, uncertainty, loneliness low social support, sensitivity cognitive inflexibility such immune dysregulation, alterations angiotensin system hypothalamus-pituitary-adrenal axis activation potential risk Treatment comprise pharmacotherapy selective serotonin/noradrenaline reuptake inhibitors (internet-/computer-based) behavioral psychotherapy, possibly augmented by mindfulness-based techniques, physical exercise non-invasive brain stimulation. Provided corroboration currently suggested increased syndrome future large-scale, prospective studies, standardized screening patients infection – particularly individuals psychiatric consultation liaison service should established provide preventive therapeutic interventions early possible.

Language: Английский

Citations

2